UroGen Pharma Ltd logo

UroGen Pharma Ltd

NAS:URGN (USA)  
$ 13.31 +0.3 (+2.3%) 08:08 PM EST
At Loss
Market Cap:
$ 411.44M
Enterprise V:
$ 354.31M
Volume:
103.66K
Avg Vol (2M):
261.92K
Also Trade In:
Volume:
103.66K
At Loss
Avg Vol (2M):
261.92K

Business Description

Description
UroGen Pharma Ltd is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative solutions that treat urothelial and specialty cancers. The company has an innovative and broad pipeline of product candidates that can overcome the deficiencies of current treatment options for a variety of urological conditions with a focus on uro-oncology. Its lead product candidates, UGN-101 and UGN-102, are proprietary formulations of the chemotherapy drug Mitomycin C, or MMC, a generic drug, which is used off-label for urothelial cancer treatment only in a water-based formulation as an adjuvant, or supplemental post-surgery, therapy.
Name Current Vs Industry Vs History
Cash-To-Debt 1.48
Equity-to-Asset -0.22
Debt-to-Equity -2.37
Debt-to-EBITDA -1.13
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -3.87
Distress
Grey
Safe
Beneish M-Score -1.64
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC
Name Current Vs Industry Vs History
5-Day RSI 63.15
9-Day RSI 64.08
14-Day RSI 58.75
6-1 Month Momentum % 18.79
12-1 Month Momentum % 37.9

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 7.06
Quick Ratio 6.87
Cash Ratio 5.72
Days Inventory 192.65
Days Sales Outstanding 59.49
Days Payable 185.59

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -3.2
Shareholder Yield % -10.39

Financials (Next Earnings Date:2024-03-15 Est.)

URGN's 30-Y Financials
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Gurus Latest Trades with NAS:URGN

No Available Data

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014

UroGen Pharma Ltd Executives

Details

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 77.275
EPS (TTM) ($) -4.23
Beta 0.81
Volatility % 123.56
14-Day RSI 58.75
14-Day ATR ($) 0.685188
20-Day SMA ($) 12.2015
12-1 Month Momentum % 37.9
52-Week Range ($) 7.15 - 24.13
Shares Outstanding (Mil) 30.87

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 3
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

UroGen Pharma Ltd Filings

Filing Date Document Date Form
No Filing Data

UroGen Pharma Ltd Stock Events

Event Date Price($)
No Event Data

UroGen Pharma Ltd Frequently Asked Questions

What is UroGen Pharma Ltd(URGN)'s stock price today?
The current price of URGN is $13.31. The 52 week high of URGN is $24.13 and 52 week low is $7.15.
When is next earnings date of UroGen Pharma Ltd(URGN)?
The next earnings date of UroGen Pharma Ltd(URGN) is 2024-03-15 Est..
Does UroGen Pharma Ltd(URGN) pay dividends? If so, how much?
UroGen Pharma Ltd(URGN) does not pay dividend.

Press Release

Subject Date
No Press Release

Headlines

See More
  • 1
No news.
  • 1